Clinical trial eligibility criteria: how to read inclusion and exclusion rules for a peptide study

01

What inclusion and exclusion criteria do

ClinicalTrials.gov defines eligibility criteria as the requirements people must meet or characteristics they must have to participate. Inclusion criteria state what must be present. Exclusion criteria state what prevents participation. Together they help researchers protect participants and enroll a group capable of answering the study question.

A criterion can be clinical or practical. Examples include a confirmed diagnosis, age range, laboratory threshold, prior treatment, medication washout, organ function, pregnancy status, another condition, ability to attend visits, or a defined time since an event. The meaning depends on the full protocol, not the heading alone.

02

How to read the ClinicalTrials.gov record

Open the current study record and check the participation-criteria section alongside study type, phase, intervention, recruitment status, dates, enrollment, contacts, and locations. Confirm whether the study is interventional or observational and whether it is actually recruiting at a location a person could use. An overall recruiting label does not guarantee that every listed site is open.

Note whether age is expressed in years, months, or another unit and whether the record accepts healthy volunteers. Read technical terms with a clinician or the study contact rather than guessing. The registry is a disclosure and search system; ClinicalTrials.gov says it does not directly enroll people or validate the scientific accuracy of every posted record.

03

Public criteria are the start of screening, not the result

A person who appears to match the public criteria may still be ineligible after records, examination, laboratory work, imaging, medication review, or protocol-specific interpretation. Conversely, a phrase that looks disqualifying may need clarification from qualified study staff. Never stop, start, or hide a medicine or condition to fit a criterion.

Use the study contact listed for the active location to ask which records are needed, whether prescreening is available, who pays for screening tests, and how long a decision may take. A personal clinician can help interpret health implications but cannot override the research protocol. Screening is not the same as receiving the investigational product.

04

Eligibility shapes how trial results generalize

When reading results, compare the enrolled population with the people described in a marketing claim. A trial limited to adults with a confirmed disease, particular laboratory range, previous treatment, and close monitoring does not directly establish outcomes in healthy consumers or people excluded for safety reasons. The product, formulation, route, and background care must also match.

Restrictive criteria can improve safety or reduce variability but narrow applicability. Broad criteria may make a study more representative while introducing more variation. Neither is automatically better. The key is to state who was studied and avoid extending average results beyond evidence without qualification.

05

Eligibility is separate from informed consent and access

Meeting eligibility criteria does not create an obligation to join. Informed consent is an ongoing process in which research staff explain procedures, time, known risks and potential benefits, alternatives, confidentiality, costs or payments, contacts, and the voluntary nature of participation. A prospective participant should receive time for questions and a copy of the consent information.

Participation also does not guarantee benefit, assignment to the investigational treatment, payment, free care, or continued access after the study. ClinicalTrials.gov advises contacting the study team about costs and payments because those details may not appear in the record. Expanded access is a separate pathway and is not promised merely because someone cannot join a trial.

06

A safe contact and verification checklist

Before sharing records, confirm the NCT number, sponsor, facility, named contact, email domain, location status, and record update date. Use contact information from the official registry or institution rather than a social-media recruiter. Ask whether the site is enrolling, whether remote participation is possible, what screening requires, which costs are covered, and whom to contact for research-related injury or questions.

Do not pay an online peptide seller for supposed trial access or assume a research-use product is the study intervention. A legitimate clinical trial has a protocol, responsible sponsor or investigator, consent process, oversight, and defined supply chain. Report suspicious recruitment through the appropriate institution or regulator and discuss personal treatment decisions with a licensed clinician.

Save the record version and compare its history when a recruiter describes criteria or locations that are not visible in the current entry. Study information can legitimately change, but material differences should be explained by the listed team. Never send identity documents, payment, or complete medical records to an unverified contact merely because a message cites a real NCT number.

• →NCT number and official title
• →Current overall and site-level status
• →Sponsor and responsible party
• →Inclusion and exclusion criteria
• →Screening steps
• →Travel, time, costs, and payment
• →Randomization and intervention access
• →Consent and study contacts